OncoMatch/Clinical Trials/Non-Hodgkin Lymphoma (NHL)
Non-Hodgkin Lymphoma (NHL) Clinical Trials
OncoMatch filters Non-Hodgkin Lymphoma (NHL) trials by the molecular markers that determine eligibility — CD274, MYC, CD19, CD20, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Non-Hodgkin Lymphoma (NHL) trials
These are the molecular markers most commonly required or evaluated in Non-Hodgkin Lymphoma (NHL) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Non-Hodgkin Lymphoma (NHL) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Genmab
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Merck Sharp & Dohme LLC
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development, LLC
How OncoMatch finds Non-Hodgkin Lymphoma (NHL) trials for you
AI reads the protocol
Every Non-Hodgkin Lymphoma (NHL) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Non-Hodgkin Lymphoma (NHL) and mark your biomarker results — CD274, MYC, CD19 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.